What primary care providers need to know about preexposure prophylaxis for HIV prevention: A narrative review

Annals of Internal Medicine

Volumn 157, Issue 7, 2012, Pages 490-497

  Krakower, Douglas ^a   Mayer, Kenneth H ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b FENWAY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR;

BONE DENSITY; CREATININE BLOOD LEVEL; DOWN REGULATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GEL; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HEPATITIS B; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE HOMOSEXUAL; MUCOSAL IMMUNITY; NAUSEA; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

EID: 84868333687     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-7-201210020-00510     Document Type: Review

References (62)

1. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global AIDS Epidemic 2010. Accessed at www.unaids.org/GlobalReport/default.htm on 1 June 2012.
2. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al; HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502. [PMID: 21826193]
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74. [PMID: 20643915]
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. [PMID: 21091279]
5. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 Jul 11. [Epub ahead of print] [PMID: 22784037]
6. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al; the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012 Jul 11. [Epub ahead of print] [PMID: 22784038]
7. Vastag, B. FDA panel recommends approval of drug to prevent HIV infection. Washington Post. 10 May 2012. Accessed at www.washingtonpost.com/national /health-science/fda-advisory-committee-recommends-approval-of-first-drug-for-preventing-hiv/2012/05/10/gIQA5YzdGU_story.html on 17 July 2012.
8. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al; the FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012 Jul 11. [Epub ahead of print] [PMID:22784040]
9. FHI 360. FEM-PrEP June 2011 Update. 18 April 2011. Accessed at www.fhi.org/en/Research/Projects/FEM-PrEP.htm on 1 June 2012.
10. Microbicides Trial Network. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women [press release]. Pittsburgh, PA: Microbicides Trial Network; 28 November 2011. Accessed at www.mtnstopshiv.org/node/3909 on 1 June 2012.
11. Donnell D, Baeten J, Hendrix C, Bumpus N, Bangsberg D, Haberer J, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda [Abstract]. Presented at 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 5-8 March 2012. Abstract 30. Accessed at www.retroconference.org/2012b/Abstracts/43156.htm on 1 June 2012.
12. Roberts L, Passmore JA, Williamson C, Little F, Naranbhai V, Sibeko S, et al. Genital tract inflammation in women participating in the CAPRISA TFV microbicide trial who became infected with HIV: a mechanism for breakthrough infection? [Abstract]. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 February-2 March 2011. Abstract 991. Accesssed at http: //retroconference.org/2011/Abstracts/41472.htm on 14 July 2012.
13. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2012;379:2409-11. [PMID: 22153566]
14. McGowan I, Hoesley C, Andrew P, Janocko L, Dai J, Carballo-Diéguez A, et al. MTN-007: a phase 1 randomized, double-blind, placebo-controlled rectal safety and acceptability study of tenofovir 1% gel [Abstract]. Presented at 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 5-8 March 2012. Abstract 34LB. Accessed at www.retroconference.org/2012b /Abstracts/45234.htm on 1 June 2012.
15. Follow-on African Consortium for Tenofovir Studies. FACTS 001. Accessed at www.facts-consortium.co.za/?page_id_83 on 1 June 2012.
16. AIDS Vaccine Advocacy Coalition. Ongoing and Planned Pre-Exposure Prophylaxis (PrEP) Trials. April 2012. Accessed at www.avac.org/ht/a /GetDocumentAction/i/3113 on 18 July 2012.
17. Kwara A, Delong A, Rezk N, Hogan J, Burtwell H, Chapman S, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIVinfected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46:719-25. [PMID: 18220480]
18. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS. 2007;21:1899-907. [PMID:17721097]
19. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009; 51: 416-23. [PMID: 19623693]
20. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004;35:120-5. [PMID: 14722442]
21. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359: 727-32. [PMID: 11888582]
22. Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntryre JA, Harlow SD. Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet. 2004;363:1415-21. [PMID:15121402]
23. Shannon K, Csete J. Violence, condom negotiation, and HIV/STI risk among sex workers. JAMA. 2010;304:573-4. [PMID: 20682941]
24. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al; HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543-51. [PMID: 16470118]
25. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49:298-308. [PMID: 18845956]
26. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med. 2008;16:122-6. [PMID: 18838746]
27. Grohskopf L, Gvetadze R, Pathak S, O'Hara B, Mayer K, Liu A, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM) [Abstract]. Presented at XVIII International AIDS Conference, Vienna, Austria, 18-23 July 2010. Abstract FRLBC102. Accessed at http://pag.aids2010.org/Abstracts.aspx?AID_17777 on 1 June 2012.
28. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir preexposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011; 6: e23688. [PMID: 21897852]
29. Mulligan K, Glidden DV, Gonzales P, Ramirez-Cardich ME, Liu A, Namwongprom S, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study [Abstract]. Presented at 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 February-2 March 2011. Abstract 94LB. Accessed at www.retroconference.org/2011/Abstracts/42550.htm on 1 June 2012.
30. Anton P, Cranston R, Carballo-Dieguez A, Kashuba A, Khanukhova E, Elliott J, et al. RMP-02/MTN-006: a phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF [Abstract]. Presented at 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 February-2 March 2011. Abstract 34LB. Accessed at www.retroconference.org /2011/Abstracts/42556.htm on 1 June 2012.
31. Grant R, Lama J, Glidden D; iPrEx Study Team. Pre-exposure chemprophylaxis for prevention of HIV among trans-women and MSM: iPREx study [Abstract]. Presented at 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 February-2 March 2011. Abstract 92. Accessed at www.retroconference.org/2011/Abstracts/42567.htm on 1 June 2012.
32. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-8. [PMID: 21270743]
33. Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis. 2009;199:974-81. [PMID: 19231993]
34. Nüesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, et al. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS. 2008; 22: 152-4. [PMID: 18090405]
35. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2: e27. [PMID: 17525796]
36. Abbas U, Glaubius R, Mubayi A, Hood G, Mellors J. Predicting the impact of ART and PrEP with overlapping regimens on HIV transmission and drug resistance in South Africa [Abstract]. Presented at 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 February-2 March 2011. Abstract 98LB. Accessed at www.retroconference.org/2011/Abstracts/42475.htm on 1 June 2012.
37. Amico KR, Liu A, McMahan V, Anderson P, Lama JR, Guanira J, et al. Adherence indicators and PrEP drug levels in the iPrEx study [Abstract]. Presented at 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 February-2 March 2011. Abstract 95LB. Accesssed at www.retroconference.org/2011/Abstracts/42627.htm on 1 June 2012.
38. Mutua G, Sanders E, Kamali A, Kibengo F, Mugo P, Anzala O, et al. Safety and adherence to intermittent emtricitabine/tenofovir for HIV pre-exposure prophylaxis (PrEP) in Kenya and Uganda [Abstract]. Presented at XVIII International AIDS Conference, Vienna, Austria, 18-23 July 2010. Abstract MOPE0369. Accessed at http://pag.aids2010.org/Abstracts.aspx?AID_2521 on 1 June 2012.
39. HIV Prevention Trials Network. HPTN 067: The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP). Accessed at www.hptn.org/research_studies/hptn067.asp on 17 July 2012.
40. Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7:e33119. [PMID: 22470438]
41. Mayer K, White J, Krakower D, Mimiaga MJ. Evolution of physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention [Abstract]. Presented at 49th Annual Meeting of the Infectious Diseases Society of America, Boston, 20-23 October 2011. Abstract 493. Accessed at http://idsa.confex.com/idsa/2011/webprogram/Paper31210.html on 1 June 2012.
42. White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26:395-405. [PMID: 22694239]
43. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and costeffectiveness. AIDS. 2008;22:1829-39. [PMID: 18753932]
44. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156:541-50. [PMID: 22508731]
45. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin Í, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8: e1001123. [PMID: 22110407]
46. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54:1504-13. [PMID: 22474224]
47. AIDS Vaccine Advocacy Coalition. Summary on AVAC Think Tank on PrEP Financing in the US. 14 January 2009. Accessed at www.avac.org/ht/a /GetDocumentAction/i/3529 on 1 June 2012.
48. National Alliance of State & Territorial AIDS Directors. The ADAP Watch. 17 May 2012. Accessed at www.nastad.org/Docs/115231_ADAP %20Watch%20update%20-%205.18.12.pdf on 1 June 2012.
49. United Nations General Assembly Special Session on HIV/AIDS. UNGASS County Progress Report Thailand: Reporting Period January 2008-December 2009. Accessed at http://data.unaids.org/pub/Report/2010/thailand _2010_country_progress_report_en.pdf on 1 June 2012.
50. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America-forgotten but not gone. N Engl J Med. 2010;362:967-70. [PMID: 20147707]
51. Epstein RM, Morse DS, Frankel RM, Frarey L, Anderson K, Beckman HB. Awkward moments in patient-physician communication about HIV risk. Ann Intern Med. 1998;128:435-42. [PMID: 9499326]
52. Vergeront JM, Reiser WJ, Krchnavek KA, Druckenmiller JK, Davis JP. Meeting the challenge of early identification of HIV infection in primary care. WMJ. 1998;97:52-61. [PMID: 9894442]
53. Centers for Disease Control and Prevention. HIV prevention practices of primary-care physicians-United States, 1992. JAMA. 1994;271:261-2. [PMID:8295276]
54. Dariotis JK, Sonenstein FL, Gates GJ, Capps R, Astone NM, Pleck JH, et al. Changes in sexual risk behavior as young men transition to adulthood. Perspect Sex Reprod Health. 2008;40:218-25. [PMID: 19067935]
55. Baral S, Sifakis F, Cleghorn F, Beyrer C. Elevated risk for HIV infection among men who have sex with men in low-and middle-income countries 2000-2006: a systematic review. PLoS Med. 2007;4:e339. [PMID: 18052602]
56. Metzger DS, Koblin B, Turner C, Navaline H, Valenti F, Holte S, et al. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000;152:99-106. [PMID: 10909945]
57. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505. [PMID:21767103]
58. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev. 2009: CD003362. [PMID: 19370585]
59. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-8. [PMID: 20537376]
60. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011:CD003510. [PMID: 21735394]
61. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337:1485-90. [PMID: 9366579]
62. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/ AIDS Rep. 2011;8:62-72. [PMID: 20941553]